Adam Feuerstein Thinks Merger May Be In Works In Biotech (CTIC, SNSS)

Adam Feuerstein, senior biotech writer at the TheStreet.com, tweeted that he thinks that Cell Therapeutics, Inc. (NASDAQ: CTIC) may buy Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS).

This is all speculation on his part, and there has been no talk of a merger between the companies.

Sunesis Pharmaceuticals, Inc. focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

Cell Therapeutics, Inc. develops, acquires, and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkins.